IGC PHARMA INC(NYSEARCA:IGC) stock News

IGC Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: ACCESS Newswire

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

9 days ago - By: ACCESS Newswire

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

14 days ago - By: ACCESS Newswire

IGC Pharma Announces Preclinical Data Demonstrating TGR-63’s Dual Action on Alzheimer’s Pathology

16 days ago - By: ACCESS Newswire

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

a month ago - By: ACCESS Newswire

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

a month ago - By: ACCESS Newswire

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

2 months ago - By: ACCESS Newswire

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

3 months ago - By: ACCESS Newswire

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

3 months ago - By: ACCESS Newswire

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

a month ago - By: ACCESS Newswire

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

a month ago - By: Benzinga - Mentions: NBY TTNP ELMD ONMD ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

a month ago - By: ACCESS Newswire

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50."

a month ago - By: ACCESS Newswire

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

3 months ago - By: Benzinga

Insights Ahead: IGC Pharma's Quarterly Earnings

2 months ago - By: ACCESS Newswire

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

2 months ago - By: Zacks Investment Research - Mentions: PINC

IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates

2 months ago - By: Zacks Investment Research - Mentions: HYPR

Hyperfine, Inc. (HYPR) Reports Q2 Loss, Lags Revenue Estimates

2 months ago - By: Zacks Investment Research - Mentions: VRCA

Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates

2 months ago - By: ACCESS Newswire

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

3 months ago - By: ACCESS Newswire

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

3 months ago - By: ACCESS Newswire

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

3 months ago - By: ACCESS Newswire

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025

4 months ago - By: ACCESS Newswire

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

4 months ago - By: Zacks Investment Research - Mentions: PSTV

Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates

5 months ago - By: ACCESS Newswire

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

5 months ago - By: ACCESS Newswire

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

6 months ago - By: ACCESS Newswire

IGC PHARMA INC (IGC) Stock News

IGC Latest News, Press Relases and Analysis

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

IGC Pharma Announces Preclinical Data Demonstrating TGR-63’s Dual Action on Alzheimer’s Pathology

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

12 Health Care Stocks Moving In Wednesday's Intraday Session

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50."

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

Insights Ahead: IGC Pharma's Quarterly Earnings

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates

Hyperfine, Inc. (HYPR) Reports Q2 Loss, Lags Revenue Estimates

Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

IGC Pharma Welcomes Strategic Investment from Advisors